NCT03359304Not yet recruiting
The Neurofibromatosis-associated Tumor Biobank
Establishment of Neurofibromatosis-associated Tumours Biobank for Future Genomic-based Research Aiming at Improved Outcome Prediction
Source: ClinicalTrials.gov · Last updated 2 Dec 2017 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Neurofibromatosis-associated Tumor is very rare bone tumor. The investigator set up the biobank to ensure every patient has the chance to participate in future research
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 300 (estimated)
- First submitted
- 25 Nov 2017
- Start date
- 1 Mar 2018
- Primary completion date
- 1 Mar 2023
- Lead sponsor
- Ren tingting
- Diseases
- Childhood cancers
- NCT number
- NCT03359304
What you commit to
- Study type: Observational
- Planned participants: 300
- From 1 Mar 2018 to the primary completion date, 1 Mar 2023
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- non-asian
Who the study is looking for
- Proband Inclusion criteria: A diagnosis or suspected diagnosis of neurofibromatosis-associated tumor Family member inclusion criteria: Biological parents and full biological siblings of a case diagnosed with neurofibromatosis-associated tumor
Sex: All
This page is information, not medical advice. Discuss any trial with your doctor.